e1905 is the trial ID number for a trial named Azacitidine With or Without MS-275 in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Azacitidine is Vidaza, used in treatment of MDS.
MS-275 inhibits HDACs (histone deacetylases). Since HDACs regulate gene transcription, HDAC inhibitors have the potential to reduce the production of targeted (disease) cells.
This trial will study the safety and efficacy of MS-275 when given in conjunction with Vidaza. The study details can be found at clinicaltrials.gov
and at the two centers running the trial: Johns Hopkins
. A previous study
found MS-275 to have potential benefits for MDS treatment and therefore to be worth further study.